ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the pricing of its previously announced underwritten public offering of 3,676,471 shares of its common stock at a price to […]
Financial
LindaCare Appoints Donald Deyo to Executive Chairman and Head of US Operations
LEUVEN, Belgium and STAMFORD, Conn., June 9, 2020 /PRNewswire/ — LindaCare is pleased to announce the appointment of Donald L. Deyo into the new roles of Executive Chairman of the LindaCare NV and President and CEO of the US subsidiary, LindaCare Inc. Deyo has served as Chairman of the Board for the Company since 2017. LindaCare […]
Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
FREMONT, Calif., June 8, 2020 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Justin Renz to the position of Chief Financial Officer. Mr. Renz, a highly accomplished leader with over 20 years of […]
XyloCor Therapeutics Names Alexander Gaidamaka, PhD, Senior Vice President of Technology, Manufacturing & Quality
PHILADELPHIA–(BUSINESS WIRE)–XyloCor Therapeutics, a private clinical‑stage biopharmaceutical company focused on the development of gene therapy for unmet needs in cardiovascular disease, strengthens its leadership team with the appointment of Alexander Gaidamaka, PhD, as Senior Vice President of Technology, Manufacturing & Quality. Dr. Gaidamaka brings a wealth of product development, regulatory […]
InspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Option in Full and Closing of $11.5 Million Follow-On Underwritten Public Offering
TEL AVIV, Israel, June 08, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the closing, on June 5, 2020, of its $11.5 million follow-on underwritten public offering, which included […]
Neovasc Announces Closing of Final Convertible Debt Issuance for Gross Proceeds of US$5.0 Million
VANCOUVER and MINNEAPOLIS, MN, June 04, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that, further to its press release dated […]
InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering
TEL AVIV, Israel, June 03, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 22,222,200 units at a price to the […]
Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it received notice from The Nasdaq Stock Market, LLC (“Nasdaq”) on June 2, 2020 indicating that the Company […]
BioSig Technologies Expands Intellectual Property Portfolio
Westport, CT, June 03, 2020 (GLOBE NEWSWIRE) — U.S. Patent and Trademark Office awards Company additional patent for PURE EP™ System Five patent applications filed by ViralClear Pharmaceuticals, Inc., covering its orally administered broad-spectrum anti-viral solution for the treatment of COVID-19 BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), […]
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering
WESTMINSTER, Colo., June 03, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the closing of its previously announced registered direct offering with certain institutional and accredited investors of 348,000 shares of […]
Recent
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease
Conavi Medical Announces FDA 510(k) Clearance of its Next-Generation Hybrid IVUS-OCT System for Intravascular Imaging
Popular
- No commented posts yet